Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for ImmunityBio (IBRX) over the last 7 years, with Q3 2025 value amounting to $32.0 million.

  • ImmunityBio's Receivables - Net rose 66685.03% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.0 million, marking a year-over-year increase of 66685.03%. This contributed to the annual value of $2.4 million for FY2024, which is N/A changed from last year.
  • ImmunityBio's Receivables - Net amounted to $32.0 million in Q3 2025, which was up 66685.03% from $22.1 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Receivables - Net peaked at $32.0 million during Q3 2025, and registered a low of $1.0 million during Q2 2024.
  • Over the past 4 years, ImmunityBio's median Receivables - Net value was $1.8 million (recorded in 2022), while the average stood at $8.4 million.
  • Per our database at Business Quant, ImmunityBio's Receivables - Net plummeted by 2053.85% in 2024 and then soared by 204191.67% in 2025.
  • Quarter analysis of 4 years shows ImmunityBio's Receivables - Net stood at $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then surged by 81.54% to $2.4 million in 2024, then soared by 1256.61% to $32.0 million in 2025.
  • Its last three reported values are $32.0 million in Q3 2025, $22.1 million for Q2 2025, and $17.0 million during Q1 2025.